CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 28, 2019--
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host
its fourth quarter and full-year 2018 investor update conference call
and webcast at 8:30 a.m. Eastern Time on Wednesday, February 13, 2019.
Individuals interested in participating in the call should dial (866)
393-4306 (U.S. and Canada) or (734) 385-2616 (international) using
conference ID number 8449987. To access the webcast, please visit the
Investors section of Ironwood’s website at www.ironwoodpharma.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
The call will be available for replay via telephone starting February
13, 2019 at approximately 1:30 p.m. Eastern Time, running through 11:59
p.m. Eastern Time on February 27, 2019. To listen to the replay, dial
(855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using
conference ID number 8449987. The archived webcast will be available on
Ironwood’s website for 14 days beginning approximately one hour after
the call has completed.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a commercial biotechnology
company focused on creating medicines that make a difference for
patients, building value for our fellow shareholders, and empowering our
passionate team. We discovered, developed and are commercializing
linaclotide, the U.S. branded prescription market leader for adults with
irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic
constipation (CIC). Our pipeline priorities for linaclotide include a
Phase IIIb trial evaluating its efficacy and safety on multiple
abdominal symptoms, including abdominal bloating, pain, and discomfort
in adult patients with IBS-C, as well as research into a formulation of
linaclotide designed to relieve abdominal pain associated with IBS.
We are also advancing a pipeline of innovative product candidates in
areas of significant unmet need, including persistent gastroesophageal
reflux disease, diabetic nephropathy, heart failure with preserved
ejection fraction and sickle cell disease. Ironwood was founded in 1998
and is headquartered in Cambridge, Mass. For more information, please
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190128005733/en/
Source: Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Meredith Kaya, 617-374-5082
President, Investor Relations and Corporate Communications